This article reports the results of a retrospective analysis investigating HTX-019 as a 30-min intravenous infusion in patients receiving chemotherapy for cancer. A total of 100 patients were included in the analysis and no treatment-emergent adverse events were related to HTX-019. The authors concluded that HTX-019 is safe and well tolerated in cancer patients receiving chemotherapy.
Aim: The neurokinin 1 receptor antagonist HTX-019 (CINVANTI® [aprepitant injectable emulsion]) was approved for preventing chemotherapy-induced nausea and vomiting based on bioequivalence studies in healthy volunteers. The objective of this study was to evaluate HTX-019 safety in cancer patients. Patients & methods: This retrospective analysis evaluated the safety of HTX-019 130 mg 30-min intravenous infusion, as part of a three-drug antiemetic regimen. Results: No treatment-emergent adverse events (TEAEs) were deemed related to HTX-019. During treatment cycles, 3 of 100 patients developed five reversible TEAEs: dyspnea, hot flash, pain, nausea and visual disturbance. Between cycles, 6 patients had TEAEs of dizziness (3 patients), infusion-site events (2 patients) and headache (2 patients). Conclusion: HTX-019 is safe in cancer patients receiving chemotherapy.